maybe it is Roche, but one of my software clients facilitates clinical trials, SNTA being one of their customers. My source said a deal is eminent (already signed) and is a multi-national. She thought Eisa, but Roche was also tossed around as a candidate. I would NOT be short right now!
I guess the rumors are true, they brought Steven Bernitz in because he is a deal maker--new must be starting to filter out and the short are starting to cover should cont to go up later in afternoon and on Monday
This is what I am hearing…..not sure how far along they are, but Roche was the company I was told. The person I was talking to didn't even know who Roche was. I had to ask him twice to make sure that is what he heard…..needless to say, I told him that if that is what he heard, it is a very big deal.
Sentiment: Strong Buy
During the 3Q conference call a question was asked about whether a partnership was being discussed by Thomas Wei of Jefferies LLC. Here is a part of the transcript from that meeting:
Thomas Wei - Jefferies LLC, Research Division
Okay. And then just lastly, from a funding standpoint, I guess any update on how things are progressing on a partnership for ganetespib now that World Lung is over and you've had a chance to get some feedback from perspective parties there? And what other options do you have besides some equity financing to help fund the GALAXY-2 trials?
Keith S. Ehrlich - Chief Financial Officer, Principal Accounting Officer and Vice President of Administration & Finance
The discussions are, we're in advance discussions. They're going well. We were certainly -- a lot of us were waiting for the World Lung data. I think as Vojo mentioned, we're very encouraged by the positive reception in Sydney to the data in the Lung Community. And I think that will have a positive impact, although I think most expectations on the data are consistent before and after that meeting. Beyond that, I couldn't really give any guidance on timing. We've never really guided on-timing discussions. In addition, we continue to look at all -- we always look opportunistically at all options.
Sentiment: Strong Buy